Similar Papers

Paper Title
Journal
Date
Author
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen.
Xuezhi Hao ... Puyuan Xing
Journal of Cancer | VOL. 11
Xuezhi Hao, et. al.Xuezhi Hao ... Puyuan Xing
01 Jan 2020
Cemiplimab + Chemo Shows Clinical Benefit in Advanced NSCLC
Catlin Nalley
Oncology Times | VOL. 45
Catlin NalleyCatlin Nalley
20 Jun 2023
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy
Giovanni Giuliani ... Stefan Walzer
Lung Cancer | VOL. 69
Giovanni Giuliani, et. al.Giovanni Giuliani ... Stefan Walzer
01 Aug 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany
Helge G Bischoff ... Mark Nuijten
Lung Cancer | VOL. 69
Helge G Bischoff, et. al.Helge G Bischoff ... Mark Nuijten
01 Aug 2010
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Comments on The Study of Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma
Yue-Can Zeng ... Yi Wang
Annals of Oncology | VOL. -
Yue-Can Zeng, et. al.Yue-Can Zeng ... Yi Wang
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.